About
Cell Therapies, Antibodies, Nanobodies
Areas of Focus
Categories
NanotechBiologics & BiopharmaceuticalStem Cell & Cellular TherapyAntibodyChina
Clinical Trials (43)
View allTotal Trials
43
As Lead Sponsor
39
As Collaborator
4
Total Enrollment
677
By Phase
PHASE2: 2EARLY_PHASE1: 15NA: 8PHASE1: 8PHASE1/PHASE2: 10
By Status
UNKNOWN: 30NOT_YET_RECRUITING: 6RECRUITING: 6COMPLETED: 1
Clinical Trials Pipeline43 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
Today
Hover over trial bars to see details
Recent Trials
NCT07188610Lead Sponsor
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
PHASE2Not yet recruiting
100 participants
Started: Oct 1, 2025 · Completed: Oct 1, 2027
NCT06982534Lead Sponsor
Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.
EARLY_PHASE1Not yet recruiting
24 participants
Started: Jun 30, 2025 · Completed: Jan 31, 2040
NCT06982547Lead Sponsor
Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection
EARLY_PHASE1Not yet recruiting
24 participants
Started: Jun 30, 2025 · Completed: Jun 30, 2040
NCT06970951Lead Sponsor
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
EARLY_PHASE1Not yet recruiting
15 participants
Started: May 18, 2025 · Completed: Apr 30, 2027
NCT06871644Lead Sponsor
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
NANot yet recruiting
18 participants
Started: Mar 18, 2025 · Completed: Mar 31, 2027
Locations (1)
Headquarters
Suzhou, China
Map
Loading map...